{"pmid":32472703,"title":"COVID-19 pneumonia treated with Sarilumab: a clinical series of eight patients.","text":["COVID-19 pneumonia treated with Sarilumab: a clinical series of eight patients.","The development of cytokine release syndrome and T cell abnormalities plays a key role in the progression of Coronavirus disease in 2019 (COVID-19). Under these circumstances, persistent viral stimulation leads to a significant increase in circulating cytokines such as interleukin (IL) -6, IL-10 and TNF-alpha. We describe a clinical series of eight patients treated with Sarilumab an IL-6R inhibitor administered early in Covid-19 pneumonia. This article is protected by copyright. All rights reserved.","J Med Virol","Benucci, Maurizio","Giannasi, Gianfranco","Cecchini, Paolo","Gobbi, Francesca Li","Damiani, Arianna","Grossi, Valentina","Infantino, Maria","Manfredi, Mariangela","32472703"],"abstract":["The development of cytokine release syndrome and T cell abnormalities plays a key role in the progression of Coronavirus disease in 2019 (COVID-19). Under these circumstances, persistent viral stimulation leads to a significant increase in circulating cytokines such as interleukin (IL) -6, IL-10 and TNF-alpha. We describe a clinical series of eight patients treated with Sarilumab an IL-6R inhibitor administered early in Covid-19 pneumonia. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Benucci, Maurizio","Giannasi, Gianfranco","Cecchini, Paolo","Gobbi, Francesca Li","Damiani, Arianna","Grossi, Valentina","Infantino, Maria","Manfredi, Mariangela"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472703","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26062","keywords":["covid-19","interleukin-6","sarilumab"],"topics":["Treatment"],"weight":1,"_version_":1668255193359187969,"score":9.490897,"similar":[{"pmid":32462717,"title":"COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","text":["COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved.","J Med Virol","Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy","32462717"],"abstract":["COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462717","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26078","keywords":["cytokine storm","il6r antagonist","sarilumab","therapeutic option","tocilizumab"],"e_drugs":["tocilizumab","sarilumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521235992576,"score":200.38853},{"pmid":32470153,"title":"Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19.","text":["Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19.","OBJECTIVE: To investigate the inflammatory factors and lymphocyte subsets which play an important role in the course of severe COVID-19. METHODS: A total of 27 patients with severe COVID-19 who were admitted to Tongji Hospital in Wuhan from 1 to 21 February 2020 were recruited to the study. The characteristics of interleukin (IL)-1beta, IL-2 receptor (IL-2R), IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-alpha, C-reactive protein (CRP), serum ferritin and procalcitonin (PCT), and lymphocyte subsets of these patients were retrospectively compared before and after treatment. RESULTS: Before treatment, there was no significant difference in most inflammatory factors (IL-1beta, IL-2R, IL-6, IL-8, IL-10, CRP and serum ferritin) between male and female patients. Levels of IL-2R, IL-6, TNF-alpha and CRP decreased significantly after treatment, followed by IL-8, IL-10 and PCT. Serum Ferritin was increased in all patients before treatment, but did not decrease significantly after treatment. IL-1beta was normal in most patients before treatment. Lymphopenia was common among these patients with severe COVID-19. Analysis of lymphocyte subsets showed that CD4(+) and particularly CD8(+) T lymphocytes increased significantly after treatment. However, B lymphocytes and natural killer cells showed no significant changes after treatment. CONCLUSIONS: A pro-inflammatory response and decreased level of T lymphocytes were associated with severe COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Ni, Ming","Tian, Fang-Bing","Xiang, Dan-Dan","Yu, Bing","32470153"],"abstract":["OBJECTIVE: To investigate the inflammatory factors and lymphocyte subsets which play an important role in the course of severe COVID-19. METHODS: A total of 27 patients with severe COVID-19 who were admitted to Tongji Hospital in Wuhan from 1 to 21 February 2020 were recruited to the study. The characteristics of interleukin (IL)-1beta, IL-2 receptor (IL-2R), IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-alpha, C-reactive protein (CRP), serum ferritin and procalcitonin (PCT), and lymphocyte subsets of these patients were retrospectively compared before and after treatment. RESULTS: Before treatment, there was no significant difference in most inflammatory factors (IL-1beta, IL-2R, IL-6, IL-8, IL-10, CRP and serum ferritin) between male and female patients. Levels of IL-2R, IL-6, TNF-alpha and CRP decreased significantly after treatment, followed by IL-8, IL-10 and PCT. Serum Ferritin was increased in all patients before treatment, but did not decrease significantly after treatment. IL-1beta was normal in most patients before treatment. Lymphopenia was common among these patients with severe COVID-19. Analysis of lymphocyte subsets showed that CD4(+) and particularly CD8(+) T lymphocytes increased significantly after treatment. However, B lymphocytes and natural killer cells showed no significant changes after treatment. CONCLUSIONS: A pro-inflammatory response and decreased level of T lymphocytes were associated with severe COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Ni, Ming","Tian, Fang-Bing","Xiang, Dan-Dan","Yu, Bing"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470153","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26070","keywords":["covid-19","lymphopenia","pro-inflammatory","severe pneumonia"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668167110047563776,"score":156.26819},{"pmid":32452979,"title":"Pediatric Crohn's Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated with Infliximab.","text":["Pediatric Crohn's Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated with Infliximab.","Coronavirus disease 2019 (COVID-19) may lead to a severe inflammatory response referred to as a cytokine storm. We describe a case of severe COVID-19 infection in a recently diagnosed pediatric Crohn's disease patient successfully treated with Tumor Necrosis Factor-alpha (TNF-alpha) blockade. The patient presented with five days of fever, an erythematous maculopapular facial rash, and abdominal pain without respiratory symptoms. SARS-CoV-2 PCR was positive. Despite inpatient treatment for COVID-19 and a perianal abscess, the patient acutely decompensated, with worsening fever, tachycardia, fluid-refractory hypotension, elevation of liver enzymes, and transformation of the rash into purpura extending from the face to the trunk, upper and lower extremities, including the palmar and plantar surfaces of the hands and feet. Cytokine profile revealed rising levels of interleukin (IL)-6, IL-8, and TNF-alpha, higher than those described in either inflammatory bowel disease (IBD) or severe COVID-19 alone. The patient was treated with infliximab for TNF-alpha blockade to address both moderately to severely active Crohn's disease and multisystem inflammatory syndrome in children (MIS-C) temporally related to COVID-19. Within hours of infliximab treatment, fever, tachycardia and hypotension resolved. Cytokine profile improved with normalization of TNF-alpha, a decrease in IL-6, and IL-8 concentrations. This case supports a role for blockade of TNF-alpha in the treatment of COVID-19 inflammatory cascade. The role of anti-TNF agents in patients with MIS-C temporally related to COVID-19 requires further investigation.","J Pediatr Gastroenterol Nutr","Dolinger, Michael T","Person, Hannibal","Smith, Rachel","Jarchin, Lauren","Pittman, Nanci","Dubinsky, Marla C","Lai, Joanne","32452979"],"abstract":["Coronavirus disease 2019 (COVID-19) may lead to a severe inflammatory response referred to as a cytokine storm. We describe a case of severe COVID-19 infection in a recently diagnosed pediatric Crohn's disease patient successfully treated with Tumor Necrosis Factor-alpha (TNF-alpha) blockade. The patient presented with five days of fever, an erythematous maculopapular facial rash, and abdominal pain without respiratory symptoms. SARS-CoV-2 PCR was positive. Despite inpatient treatment for COVID-19 and a perianal abscess, the patient acutely decompensated, with worsening fever, tachycardia, fluid-refractory hypotension, elevation of liver enzymes, and transformation of the rash into purpura extending from the face to the trunk, upper and lower extremities, including the palmar and plantar surfaces of the hands and feet. Cytokine profile revealed rising levels of interleukin (IL)-6, IL-8, and TNF-alpha, higher than those described in either inflammatory bowel disease (IBD) or severe COVID-19 alone. The patient was treated with infliximab for TNF-alpha blockade to address both moderately to severely active Crohn's disease and multisystem inflammatory syndrome in children (MIS-C) temporally related to COVID-19. Within hours of infliximab treatment, fever, tachycardia and hypotension resolved. Cytokine profile improved with normalization of TNF-alpha, a decrease in IL-6, and IL-8 concentrations. This case supports a role for blockade of TNF-alpha in the treatment of COVID-19 inflammatory cascade. The role of anti-TNF agents in patients with MIS-C temporally related to COVID-19 requires further investigation."],"journal":"J Pediatr Gastroenterol Nutr","authors":["Dolinger, Michael T","Person, Hannibal","Smith, Rachel","Jarchin, Lauren","Pittman, Nanci","Dubinsky, Marla C","Lai, Joanne"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32452979","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1097/MPG.0000000000002809","locations":["Cytokine","Cytokine","Children"],"e_drugs":["Infliximab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667983494585778176,"score":144.95563},{"pmid":32441764,"title":"Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?","text":["Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?","Clinically approved PARP inhibitors (PARPi) have a mild adverse effect profile and are well-tolerated as continuous daily oral therapy. We review the evidence that justifies the repurposing of PARPi to block the proliferation of SARS-CoV-2 and combat the life-threatening sequelae of COVID-19 by several mechanisms. PARPi's can effectively decrease IL-6, IL-1 and TNFalpha levels (key interleukins in SARS-CoV-2-induced cytokine storm) and can alleviate subsequent lung fibrosis, as demonstrated in murine experiments and clinical trials. PARPi can tune macrophages towards a tolerogenic phenotype. PARPi's may also counteract SARS-CoV-2-induced and inflammation-induced cell death and support cell survival. PARPi's had beneficial effects in animal models of acute respiratory distress syndrome (ARDS), asthma and ventilator-induced lung injury. PARPi's may potentiate the effectiveness of Tocilizumab, Anakinra, Sarilumab, Adalimumab, Canakinumab or Siltuximab therapy. In summary, the evidence suggests that PARPi therapy would benefit COVID-19 patients and trials of these drugs should be undertaken.","Br J Pharmacol","Curtin, Nicola","Banyai, Krisztian","Thaventhiran, James","Le Quesne, John","Helyes, Zsuzsanna","Bai, Peter","32441764"],"abstract":["Clinically approved PARP inhibitors (PARPi) have a mild adverse effect profile and are well-tolerated as continuous daily oral therapy. We review the evidence that justifies the repurposing of PARPi to block the proliferation of SARS-CoV-2 and combat the life-threatening sequelae of COVID-19 by several mechanisms. PARPi's can effectively decrease IL-6, IL-1 and TNFalpha levels (key interleukins in SARS-CoV-2-induced cytokine storm) and can alleviate subsequent lung fibrosis, as demonstrated in murine experiments and clinical trials. PARPi can tune macrophages towards a tolerogenic phenotype. PARPi's may also counteract SARS-CoV-2-induced and inflammation-induced cell death and support cell survival. PARPi's had beneficial effects in animal models of acute respiratory distress syndrome (ARDS), asthma and ventilator-induced lung injury. PARPi's may potentiate the effectiveness of Tocilizumab, Anakinra, Sarilumab, Adalimumab, Canakinumab or Siltuximab therapy. In summary, the evidence suggests that PARPi therapy would benefit COVID-19 patients and trials of these drugs should be undertaken."],"journal":"Br J Pharmacol","authors":["Curtin, Nicola","Banyai, Krisztian","Thaventhiran, James","Le Quesne, John","Helyes, Zsuzsanna","Bai, Peter"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441764","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bph.15137","keywords":["ards","artd","adalimumab","anakinra","covid-19","il6","nad+","parp","parp inhibitor","sars-cov-2","sarilumab","siltuximab","tocilizumab","apoptosis","chloroquine","cytokine release syndrome","hydroxychloroquine","lopinavir","lung fibrosis","macrodomain","macrophage overactivation syndrome","mechanical ventilation","nicotinamide-riboside","olaparib","remedsivir","ritonavir","rucaparib","talazoparib"],"locations":["Siltuximab"],"e_drugs":["tocilizumab","siltuximab","sarilumab","Adalimumab","canakinumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667535119436480512,"score":135.81302},{"pmid":32413619,"title":"beta-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies.","text":["beta-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies.","Coronavirus pneumonia is accompanied by rapid virus replication, where a large number of inflammatory cell infiltration and cytokine storm may lead to acute lung injury, acute respiratory distress syndrome (ARDS) and death. The uncontrolled release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6, is associated with ARDS. This constituted the first study to report on the variability in physicochemical properties of beta-glucans extracts from the same edible mushroom Lentinus edodes on the reduction of these pro-inflammatory cytokines and oxidative stress. Specifically, the impact on the immunomodulatory and cytoprotective properties of our novel in 'house' (IH-Lentinan, IHL) and a commercial (Carbosynth-Lentinan, CL) Lentinan extract were investigated using in vitro models of lung injury and macrophage phagocytosis. CL comprised higher amounts of alpha-glucans and correspondingly less beta-glucans. The two lentinan extracts demonstrated varying immunomodulatory activities. Both Lentinan extracts reduced cytokine-induced NF-kappaB activation in human alveolar epithelial A549 cells, with the IHL extract proving more effective at lower doses. In contrast, in activated THP-1 derived macrophages, the CL extract more effectively attenuated pro-inflammatory cytokine production (TNF-alpha, IL-8, IL-2, IL-6, IL-22) as well as TGF-beta and IL-10. The CL extract attenuated oxidative stress-induced early apoptosis, while the IHL extract attenuated late apoptosis. Our findings demonstrate significant physicochemical differences between Lentinan extracts, which produce differential in vitro immunomodulatory and pulmonary cytoprotective effects that may also have positive relevance to candidate COVID-19 therapeutics targeting cytokine storm.","Sci Total Environ","Murphy, Emma J","Masterson, Claire","Rezoagli, Emanuele","O'Toole, Daniel","Major, Ian","Stack, Gary D","Lynch, Mark","Laffey, John G","Rowan, Neil J","32413619"],"abstract":["Coronavirus pneumonia is accompanied by rapid virus replication, where a large number of inflammatory cell infiltration and cytokine storm may lead to acute lung injury, acute respiratory distress syndrome (ARDS) and death. The uncontrolled release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6, is associated with ARDS. This constituted the first study to report on the variability in physicochemical properties of beta-glucans extracts from the same edible mushroom Lentinus edodes on the reduction of these pro-inflammatory cytokines and oxidative stress. Specifically, the impact on the immunomodulatory and cytoprotective properties of our novel in 'house' (IH-Lentinan, IHL) and a commercial (Carbosynth-Lentinan, CL) Lentinan extract were investigated using in vitro models of lung injury and macrophage phagocytosis. CL comprised higher amounts of alpha-glucans and correspondingly less beta-glucans. The two lentinan extracts demonstrated varying immunomodulatory activities. Both Lentinan extracts reduced cytokine-induced NF-kappaB activation in human alveolar epithelial A549 cells, with the IHL extract proving more effective at lower doses. In contrast, in activated THP-1 derived macrophages, the CL extract more effectively attenuated pro-inflammatory cytokine production (TNF-alpha, IL-8, IL-2, IL-6, IL-22) as well as TGF-beta and IL-10. The CL extract attenuated oxidative stress-induced early apoptosis, while the IHL extract attenuated late apoptosis. Our findings demonstrate significant physicochemical differences between Lentinan extracts, which produce differential in vitro immunomodulatory and pulmonary cytoprotective effects that may also have positive relevance to candidate COVID-19 therapeutics targeting cytokine storm."],"journal":"Sci Total Environ","authors":["Murphy, Emma J","Masterson, Claire","Rezoagli, Emanuele","O'Toole, Daniel","Major, Ian","Stack, Gary D","Lynch, Mark","Laffey, John G","Rowan, Neil J"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413619","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.scitotenv.2020.139330","keywords":["covid-19","cytokine storm","disease mitigation","immunomodulation","medicinal mushroom","beta-glucans"],"locations":["Carbosynth-Lentinan","Lentinan","Lentinan","Lentinan","beta-Glucan"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666897319252983808,"score":132.6486}]}